Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Qiagen Monopoly In HPV Test Market Won’t Last, Judge Says

This article was originally published in The Gray Sheet

Executive Summary

A U.S. district court turned down Third Wave Technologies' claims that Qiagen engages in anti-competitive behavior in the cervical cancer screening space, but the ruling suggests the direction of the market will be in Third Wave's favor
Advertisement

Related Content

Hologic Gains HPV Test Technology In $580 Million Third Wave Purchase
Hologic Gains HPV Test Technology In $580 Million Third Wave Purchase
Gen-Probe HPV assay trial
Gen-Probe HPV assay trial
Digene Fights Antitrust Charges As Part Of HPV Diagnostics Patent Case
Digene Will Achieve Strategic Goals Faster Through Qiagen Merger, CEO Says
Digene Will Achieve Strategic Goals Faster Through Qiagen Merger, CEO Says
Advertisement
UsernamePublicRestriction

Register

MT025682

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel